Other · developed by Incyte
INCA000585 is the study code for tafasitamab, given intravenously at protocol-defined timepoints in a trial in immune thrombocytopenia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07104565 | Phase 2 | Immune Thrombocytopenia | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Immune Thrombocytopenia
Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →